RTOG Foundation Studies 3509 and 3510/RADCOMP

Status Date:  March 28, 2024  | Status:  Closed to Accrual

Pragmatic Phase III Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium

Principal Investigator

Justin E. Bekelman, MD

Primary Objective

To assess the effectiveness of proton vs. photon therapy in reducing major cardiovascular events (MCE), defined as atherosclerotic coronary heart disease or other heart disease death, myocardial infarction, coronary revascularization, or hospitalization for major cardiovascular event (heart failure, valvular disease, arrhythmia, or unstable anginaor unstable angina or other major cardiovascular event). 

Patient Population

Females or males diagnosed with pathologically (histologically) proven invasive mammary carcinoma (ductal, lobular or other) of the breast who have undergone either mastectomy or lumpectomy/local excision with any type of axillary or internal mammary node chain surgery or sampling.

Study Information

The University of Pennsylvania is the sponsor of this study. More information on this trial is available on ClinicalTrials.gov or by emailing RTOG-Membership@acr.org.

Participate in RTOG Research

To participate as an RTOG study investigator, your organization must be part of the RTOG Foundation network. Patients who wish to participate in a study must be under the care of an RTOG participating investigator. For additional information, email info@rtog.org or call 1-215-574-3173.

See our clinical trials